Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16485511 | 0.81 | SMN1; SMN2 (0.47) | KDM4EALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL17085404 | 0.69 | RET (0.46) | KDM4EALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL14701476 | 0.67 | ABCB1 (0.50) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL16485635 | 0.66 | MAPT (0.48) | KDM4EALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL16485704 | 0.66 | MAPT (0.48) | KDM4EALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL14543829 | 0.64 | TDP1 (0.57) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL14566059 | 0.64 | CYSLTR2 (0.53) | — | |
| SCHEMBL14404262 | 0.62 | MEN1 (0.41) | KDM4EALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3420378 | 0.61 | KDM4E (0.57) | KDM4EALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL14163937 | 0.61 | DGKA (0.53) | ALDH1A1MAPTSMN1; SMN2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259373-A1 | NOVEL FLAVONOID COMPOUNDS AND USES THEREOF | ARMARON BIO PTY LTD (AU) | 2015-09-17 | — | — | US | disclosed |
| WO-2014056038-A1 | NOVEL FLAVONOID COMPOUNDS AND USES THEREOF | NEUPROTECT PTY LTD (AU) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259373-A1 | NOVEL FLAVONOID COMPOUNDS AND USES THEREOF | BAX, CASP3, BAD | KDM4E 4674/4885ALDH1A1 410/4885MAPT 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.